NORTH CHICAGO, Ill.,
Nov. 9, 2021 /PRNewswire/
-- AbbVie (NYSE: ABBV) today announced new results from a
post-hoc analysis of the Phase 3 SELECT-BEYOND clinical trial
evaluating RINVOQ® (upadacitinib; 15 mg, once daily) in
patients with moderate to severe rheumatoid arthritis (RA) on
stable background of conventional synthetic disease-modifying
anti-rheumatic drugs (csDMARDs) with prior inadequate response or
intolerance to at least one biologic DMARD.
Results showed that 34% of patients receiving RINVOQ and
background csDMARDs achieved Clinical Disease Activity Index (CDAI)
remission (CDAI ≤2.8) at first occurrence of response before week
60, while 79% achieved CDAI low disease activity (LDA) (CDAI
≤10).1 Maintenance of response, defined as not losing
response at two consecutive study visits, was seen for CDAI
remission and CDAI LDA in 39% and 61% of patients, respectively, at
60 weeks.1 The study results (Abstract #1694) are among
the 38 abstracts across multiple rheumatic diseases being presented
by AbbVie at the American College of Rheumatology (ACR) Convergence
2021, taking place virtually Nov.
3-9.
"Many people living with rheumatoid arthritis continue to
experience debilitating joint pain and decreased physical
functioning despite being on therapy," said Thomas
Hudson, M.D., senior vice president, research and development,
chief scientific officer, AbbVie. "These data underscore the
potential of RINVOQ to be an important treatment option to help
people who face the daily challenges of rheumatoid arthritis."
Of patients treated with RINVOQ who lost CDAI remission, 58%
remained in CDAI LDA, and 22% recaptured remission by the analysis
cut-off date.1 Similar patterns of sustained response
were observed for remission and LDA based on Simplified Disease
Activity Index (SDAI) criteria and for DAS28(CRP)
˂2.6/≤3.2.1
"Achieving remission or low disease activity are the primary
treatment goals for people with rheumatoid arthritis. I'm
encouraged by these data, which add to the growing body of evidence
that upadacitinib may help more people living with rheumatoid
arthritis take control of this chronic, progressive disease and
reach these important treatment goals," said Professor Ronald
van Vollenhoven, M.D., Ph.D., chair of rheumatology and director,
Amsterdam Rheumatology Center (ARC).
For additional information on the safety profile of RINVOQ in
rheumatoid arthritis, as well as psoriatic arthritis and ankylosing
spondylitis, refer to the long-term safety data being
presented at ACR Convergence 2021 (Abstract #1691, Long-Term Safety
Profile of Upadacitinib in Patients with Rheumatoid Arthritis,
Psoriatic Arthritis, or Ankylosing Spondylitis).
The ACR Convergence 2021 abstracts can be found here.
About Rheumatoid Arthritis
Affecting 1.3 million
Americans, rheumatoid arthritis is a complex, systemic autoimmune
disease that occurs when the immune system mistakenly attacks
joints, creating inflammation that causes the tissue inside of
joints to thicken, damaging the bones and associated connective
tissue.2,3 Pain, fatigue and stiffness are among
the signs and symptoms of RA that can have an impact on daily
living.4 If not properly treated, RA can lead to
permanent, debilitating bone and cartilage damage.5
About SELECT-BEYOND1
SELECT-BEYOND is a
Phase 3, randomized, placebo-controlled trial that enrolled a
population of patients with moderately to severely active
rheumatoid arthritis who failed or were intolerant to as least one
prior biologic therapy. Patients on stable background conventional
synthetic (cs) DMARD(s) were randomized to receive upadacitinib 15
mg or 30 mg once-daily orally or placebo for 12 weeks, followed by
a 12-week double-blind phase where placebo patients were switched
to upadacitinib (15 mg or 30 mg); patients who completed the week
24 visit were able to enter a long-term extension of up to five
years thereafter. Initiation, change, or discontinuation of
background RA medications, including ≤2 csDMARDs, was allowed
starting at week 24.
About RINVOQ® (upadacitinib)
Discovered and
developed by AbbVie scientists, RINVOQ is a selective JAK inhibitor
that is being studied in several immune-mediated inflammatory
diseases. Based on enzymatic and cellular assays, RINVOQ
demonstrated greater inhibitory potency for JAK-1 vs JAK-2, JAK-3,
and TYK-2.6 The relevance of inhibition of specific JAK
enzymes to therapeutic effectiveness is not currently
known. RINVOQ 15 mg is approved by the U.S. Food and Drug
Administration (FDA) for adults with moderately to severely active
rheumatoid arthritis. RINVOQ 15 mg is also approved by the
European Commission for adults with moderate to severe active
rheumatoid arthritis, adults with active psoriatic arthritis and
adults with active ankylosing spondylitis. RINVOQ is approved
by the European Commission for adults (15 mg and 30 mg) and
adolescents (15 mg) with moderate to severe atopic dermatitis.
Phase 3 trials of RINVOQ in rheumatoid arthritis, atopic
dermatitis, psoriatic arthritis, axial spondyloarthritis, Crohn's
disease, ulcerative colitis, giant cell arteritis and Takayasu
arteritis are ongoing.7-14
Important Safety Information about
RINVOQ® (upadacitinib)6
RINVOQ U.S. Use and Important Safety Information
RINVOQ is a prescription medicine used to treat adults with
moderate to severe rheumatoid arthritis in whom methotrexate did
not work well or could not be tolerated. It is not known if RINVOQ
is safe and effective in children under 18 years of age.
What is the most important information I should know about
RINVOQ?
RINVOQ is a medicine that can lower the ability of your immune
system to fight infections. You should not start taking RINVOQ if
you have any kind of infection unless your healthcare provider
(HCP) tells you it is okay.
- Serious infections have happened in some people taking
RINVOQ, including tuberculosis (TB) and infections caused by
bacteria, fungi, or viruses that can spread throughout the body.
Some people have died from these infections. Your HCP should
test you for TB before starting RINVOQ and check you closely for
signs and symptoms of TB during treatment with RINVOQ. You may be
at higher risk of developing shingles (herpes zoster).
- Lymphoma and other cancers, including skin cancers, can
happen in people taking RINVOQ.
- Blood clots in the veins of the legs or lungs and arteries
are possible in some people taking RINVOQ. This may be
life-threatening and cause death.
- Tears in the stomach or intestines and changes in certain
laboratory tests can happen. Your HCP should do blood tests before
you start taking RINVOQ and while you take it. Your HCP may stop
your RINVOQ treatment for a period of time if needed because of
changes in these blood test results.
What should I tell my HCP BEFORE starting RINVOQ?
Tell your HCP if you:
- Are being treated for an infection, have an infection that
won't go away or keeps coming back, or have symptoms of an
infection such as:
-
- Fever, sweating or chills
- Shortness of breath
- Warm, red, or painful skin or sores on your body
- Muscle aches
- Feeling tired
- Blood in phlegm
- Diarrhea or stomach pain
- Cough
- Weight loss
- Burning when urinating or urinating more often than normal
- Have TB or have been in close contact with someone with
TB.
- Have had any type of cancer, hepatitis B or C, shingles (herpes
zoster), or blood clots in the veins of your legs or lungs,
diverticulitis (inflammation in parts of the large intestine), or
ulcers in your stomach or intestines.
- Have other medical conditions including liver problems, low
blood cell counts, diabetes, chronic lung disease, HIV, or a weak
immune system.
- Live, have lived, or have traveled to parts of the country that
increase your risk of getting certain kinds of fungal infections,
such as the Ohio and Mississippi River valleys and the
Southwest. If you are unsure if you've been to these areas, ask
your HCP.
- Have recently received or are scheduled to receive a vaccine.
People who take RINVOQ should not receive live vaccines.
- Are pregnant or plan to become pregnant. Based on animal
studies, RINVOQ may harm your unborn baby. Your HCP will check
whether or not you are pregnant before you start RINVOQ. You should
use effective birth control (contraception) to avoid becoming
pregnant while taking RINVOQ and for at least 4 weeks after your
last dose.
- Are breastfeeding or plan to breastfeed. RINVOQ may pass into
your breast milk. You should not breastfeed while taking RINVOQ and
for at least 6 days after your last dose.
Tell your HCP about all the medicines you
take, including prescription and over-the-counter
medicines, vitamins, and herbal supplements. RINVOQ and other
medicines may affect each other, causing side effects.
Especially tell your HCP if you take:
- Medicines for fungal or bacterial infections
- Rifampicin or phenytoin
- Medicines that affect your immune system
Ask your HCP or pharmacist if you are not sure if you are taking
any of these medicines.
What should I tell my HCP AFTER starting RINVOQ?
Tell your HCP right away if you:
- Have any symptoms of an infection. RINVOQ can make you more
likely to get infections or make any infections you have
worse.
- Have any signs or symptoms of blood clots during treatment with
RINVOQ, including:
-
- Swelling
- Sudden unexplained chest pain
- Pain or tenderness in the leg
- Shortness of breath
- Have a fever or stomach-area pain that does not go away, and a
change in your bowel habits.
What are the common side effects of RINVOQ?
These include: upper respiratory tract infections (common cold,
sinus infections), nausea, cough, and fever. These are not all the
possible side effects of RINVOQ.
RINVOQ is taken once a day with or without food. Do not split,
break, crush, or chew the tablet. Take RINVOQ exactly as your HCP
tells you to use it.
This is the most important information to know about RINVOQ.
For more information, talk to your HCP.
You are encouraged to report negative side effects of
prescription drugs to the FDA.
Visit http://www.fda.gov/medwatch or
call 1-800-FDA-1088.
If you are having difficulty paying for your medicine, AbbVie
may be able to help. Visit AbbVie.com/myAbbVieAssist to learn
more.
Please click here for the Full Prescribing
Information and Medication Guide.
Globally, prescribing information varies; refer to the
individual country product label for complete information.
About AbbVie in Rheumatology
For more than 20 years,
AbbVie has been dedicated to improving care for people living with
rheumatic diseases. Our longstanding commitment to discovering and
delivering transformative therapies is underscored by our pursuit
of cutting-edge science that improves our understanding of
promising new pathways and targets in order to help more people
living with rheumatic diseases reach their treatment goals. For
more information on AbbVie in rheumatology, visit
https://www.abbvie.com/our-science/therapeutic-focus-areas/immunology/immunology-focus-areas/rheumatology.html.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines
that solve serious health issues today and address the medical
challenges of tomorrow. We strive to have a remarkable impact on
people's lives across several key therapeutic areas: immunology,
oncology, neuroscience, eye care, virology, women's health and
gastroenterology, in addition to products and services across its
Allergan Aesthetics portfolio. For more information about AbbVie,
please visit us at www.abbvie.com. Follow @abbvie
on Twitter, Facebook, Instagram, YouTube and LinkedIn.
Forward-Looking Statements
Some statements in this news release are, or may be considered,
forward-looking statements for purposes of the Private Securities
Litigation Reform Act of 1995. The words "believe," "expect,"
"anticipate," "project" and similar expressions, among others,
generally identify forward-looking statements. AbbVie cautions that
these forward-looking statements are subject to risks and
uncertainties that may cause actual results to differ materially
from those indicated in the forward-looking statements. Such risks
and uncertainties include, but are not limited to, failure to
realize the expected benefits from AbbVie's acquisition of Allergan
plc ("Allergan"), failure to promptly and effectively integrate
Allergan's businesses, competition from other products, challenges
to intellectual property, difficulties inherent in the research and
development process, adverse litigation or government action,
changes to laws and regulations applicable to our industry and the
impact of public health outbreaks, epidemics or pandemics, such as
COVID-19. Additional information about the economic, competitive,
governmental, technological and other factors that may affect
AbbVie's operations is set forth in Item 1A, "Risk Factors," of
AbbVie's 2020 Annual Report on Form 10-K, which
has been filed with the Securities and Exchange Commission, as
updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie
undertakes no obligation to release publicly any revisions to
forward-looking statements as a result of subsequent events or
developments, except as required by law.
References:
1. Vollenhoven, R. V., et al. Sustainability of Response to
Upadacitinib Among Patients with Active Rheumatoid Arthritis
Refractory to Biological Disease-Modifying Anti-Rheumatic Drugs.
ACR Convergence 2021; Poster 1694.
2. Arthritis Foundation. What is Rheumatoid Arthritis.
Available at:
https://www.arthritis.org/about-arthritis/types/rheumatoid-arthritis/what-is-rheumatoid-arthritis.php.
Accessed on July 9, 2019
3. Hunter T, et al. Rheumatology International. Prevalence of
rheumatoid arthritis in the United
States adult population in healthcare claims databases,
2004–2014. April 2017.
4. American College of Rheumatology. Rheumatoid Arthritis.
Available at:
https://www.rheumatology.org/I-Am-A/Patient-Caregiver/Diseases-Conditions/Rheumatoid-Arthritis.
Accessed on June 7, 2019.
5. Ostrowska, M., Maśliński, W., Prochorec-Sobieszek, M.,
Nieciecki, M., & Sudoł-Szopińska, I. 2018. Cartilage and bone
damage in rheumatoid arthritis. Reumatologia, 56(2),
111–120. https://doi.org/10.5114/reum.2018.75523. Accessed on
November 1, 2021.
6. RINVOQ® (upadacitinib) [Package Insert]. North Chicago, Ill.: AbbVie Inc.
7. Burmester G.R., et al. Safety and efficacy of upadacitinib in
patients with rheumatoid arthritis and inadequate response to
conventional synthetic disease-modifying anti-rheumatic drugs
(SELECT-NEXT): a randomised, double-blind, placebo-controlled phase
3 trial. Lancet. 2018 Jun 23;391(10139):2503-2512. doi:
10.1016/S0140-6736(18)31115-2. Epub 2018 Jun 18.
8. A Study to Evaluate the Safety and Efficacy of ABT-494 for
Induction and Maintenance Therapy in Subjects With Moderately to
Severely Active Ulcerative Colitis. ClinicalTrials.gov. 2020.
Available at: https://clinicaltrials.gov/ct2/show/NCT02819635.
Accessed: June 2021.
9. A Multicenter, Randomized, Double-Blind, Placebo-Controlled
Study of ABT-494 for the Induction of Symptomatic and Endoscopic
Remission in Subjects With Moderately to Severely Active Crohn's
Disease Who Have Inadequately Responded to or Are Intolerant to
Immunomodulators or Anti-TNF Therapy. ClinicalTrials.gov. 2020.
Available at: https://clinicaltrials.gov/ct2/show/NCT02365649.
Accessed: June 2021.
10. A Study to Evaluate the Safety and Efficacy of Upadacitinib in
Participants With Giant Cell Arteritis (SELECT-GCA).
ClinicalTrials.gov. 2020. Available at:
https://clinicaltrials.gov/ct2/show/NCT03725202. Accessed:
June 2021.
11. A Study Comparing Upadacitinib (ABT-494) to Placebo in
Participants With Active Psoriatic Arthritis Who Have a History of
Inadequate Response to at Least One Biologic Disease Modifying
Anti-Rheumatic Drug (SELECT-PsA 2). Clinicaltrials.gov. 2020.
Available at: https://clinicaltrials.gov/ct2/show/NCT03104374.
Accessed: June 2021.
12. A Study to Compare Safety and Efficacy of Upadacitinib to
Dupilumab in Adult Participants With Moderate to Severe Atopic
Dermatitis (Heads Up). ClinicalTrials.gov. 2020. Available at:
https://clinicaltrials.gov/ct2/show/NCT03738397. Accessed:
June 2021.
13. A Study to Evaluate Efficacy and Safety of Upadacitinib in
Adult Participants With Axial Spondyloarthritis (SELECT AXIS 2).
ClinicalTrials.gov. 2020. Available at:
https://clinicaltrials.gov/ct2/show/NCT04169373. Accessed:
June 2021.
14. A Study to Evaluate the Efficacy and Safety of Upadacitinib in
Subjects With Takayasu Arteritis (SELECT-TAK). ClinicalTrials.gov.
2020. Available at
https://clinicaltrials.gov/ct2/show/record/NCT04161898. Accessed:
June 2021.
View original
content:https://www.prnewswire.com/news-releases/abbvie-to-present-new-long-term-analysis-evaluating-the-sustainability-of-response-to-rinvoq-upadacitinib-among-patients-with-rheumatoid-arthritis-301419810.html
SOURCE AbbVie